Genomic Signatures of Cancer: Basis for Individualized Risk Assessment, Selective Staging and Therapy
Genomic Signatures of Cancer: Basis for Individualized Risk Assessment, Selective Staging and Therapy
复制标题
DOI：
10.1002/jso.21838
复制
发表时间：
2011-05-01
影响因子：
2.5
通讯作者：
Barrett, Michael T.
中科院分区：
文献类型：
--
作者：
Baehner, Frederick L.;Lee, Mark;Barrett, Michael T.
DNA微阵列和定量实时聚合酶链反应技术的发展已经允许对数百到数千个基因的RNA表达进行精确定量。这些技术极大地影响了对癌症分子和遗传特征的研究和理解。在这篇综述文章中，选择了乳腺癌、结肠癌和肾上腺癌来说明基因组分析的原理和技术，并说明如何使用这些方法来开发个性化风险评估和个性化患者治疗的基因组特征。中华外科杂志。2011；103: 563 - 573。(C) 2011 Wiley-Liss, Inc。
The development of DNA microarray and quantitative real-time polymerase chain reaction technologies has allowed for precise quantitation of RNA expression of hundreds to thousands of genes. These technologies have significantly impacted the study and understanding of cancer in terms of its molecular and genetic characteristics. In this review article, breast cancer, colon cancer, and adrenal carcinoma have been chosen to illustrate the principle and techniques of genomic profiling and to illustrate how such methods may be used to develop genomic signatures for personalized risk assessment and to individualize patient treatment. J. Surg. Oncol. 2011;103: 563-573. (C) 2011 Wiley-Liss, Inc.